Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 18/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6364315 | 0.92 | NR1H4 (0.53) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4523652 | 0.90 | NR1H4 (0.47) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4525344 | 0.90 | NR1H4 (0.44) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4536933 | 0.87 | NR1H4 (0.40) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4530734 | 0.87 | NR1H4 (0.42) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4531261 | 0.86 | NR1H4 (0.44) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4535268 | 0.86 | NR1H4 (0.42) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4526049 | 0.85 | MAPT (0.43) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4532254 | 0.85 | NR1H4 (0.46) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4513774 | 0.85 | NR1H4 (0.42) | NR1H4ESR1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334681-A1 | 1,2,3,6-TETRAHYDROAZEPINO[4,5-B]INDOLE-5-CARBOXYLATE NUCLEAR RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110039824-A1 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors | WYETH (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010036362-A1 | 1,2,3,6-TETRAHYDROAZEPINO[4,5-B]INDOLE-5-CARBOXYLATE NUCLEAR RECEPTOR INHIBITORS | WYETH (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039824-A1 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors | NR1H4, NR1H2, NR1I3 | NR1H4 1/4885ESR1 534/4885NR3C1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.